Home
About
Services
Partners
Client Portfolio
News
Contact
Stock markets find a floor as Chinese data soothe nerves
August 8, 2019
Viacom beats quarterly revenue, profit estimates as ad revenue rebounds
August 8, 2019
0
Bayer buys BlueRock in $600 million bet on stem cell therapies
Published by
Muller&Green
at
August 8, 2019
Categories
RSS
Tags
German drugmaker Bayer is paying up to $600 million for full control of cell therapy developer BlueRock Therapeutics, stepping up investment in a promising new medical area to revive its drug development pipeline.
Powered by
WPeMatico
Muller&Green
Related posts
June 18, 2020
Chanel warns virus impact will linger on luxury sector
Read more
June 18, 2020
IMF says deeper-than-expected contraction in U.S. economy likely in second quarter
Read more
June 18, 2020
Prudential sells Jackson equity stake to Apollo-backed Athene for $500 million
Read more